Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents

Bibliography

• Payne RW, Murphy BM MM. Product development issues for PEGylated proteins. Pharm Dev Technol 2011;16:423-40
   PubMed Web of Science ®Google Scholar
• Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009;14:363-80
   PubMed Web of Science ®Google Scholar
• Omata D, Negishi Y, Hagiwara S, Enhanced gene delivery using Bubble liposomes and ultrasound for folate-PEG liposomes. J Drug Target 2012;20(4):355-63; Early Online [Feb 15]: 1-9
   PubMed Web of Science ®Google Scholar
• Chen C, Constantinou A, Deonarain M. Modulating antibody pharmacokinetics using hydrophilic polymers. Expert Opin Drug Deliv 2011;8:1221-36
   PubMed Web of Science ®Google Scholar
• Armstrong JK. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). In: Veronese FM, editor. PEGylated protein drugs. Basic Science and Clinical Applications Basel; Birkhäuser Verlag: 2009
   Google Scholar
• Garay RP, Labaune JP. Immunogenicity of Polyethylene Glycol (PEG). The Open Conference Proceedings Journal; 2011. p. 2
   Google Scholar
• Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 1983;70:124-31
   PubMedGoogle Scholar
• Tsuji J, Hirose K, Kasahara E, Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. Intl J Immunopharmacol 1985;7:725-30
   PubMed Web of Science ®Google Scholar
• Wang XY, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 2007;119:236-44
   PubMed Web of Science ®Google Scholar
• Semple SC, Harasym TO, Clow KA, Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid. J Pharmacol Expl Ther 2005;312:1020-6
   PubMed Web of Science ®Google Scholar
• Judge A, McClintock K PJ, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006;13:328-37
   PubMed Web of Science ®Google Scholar
• Sroda K, Rydlewski J, Langner M, Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett 2005;10:37-47
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang J, Lu Q, PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 2004;64:6673-8
   PubMed Web of Science ®Google Scholar
• Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 1984;74:36-9
   PubMedGoogle Scholar
• Tillmann H, Ganson NJ, Patel K, High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to PEG-Interferon. J Hepatol 2010;52(Suppl 1):S129-S
   Google Scholar
• Armstrong JK, Hempel G, Koling S, Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103-11
   PubMed Web of Science ®Google Scholar
• Sundy JS, Baraf HSB, Yood RA, Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. JAMA 2011;306:711-20
   PubMed Web of Science ®Google Scholar
• Hamad I, Hunter AC, Szebeni J, Moghimi SM. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol 2008;46:225-32
   PubMed Web of Science ®Google Scholar
• Andersson L DJ, Duncan R FP, Ford J, Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. Biomacromolecules 2005;6:914-26
   PubMed Web of Science ®Google Scholar
• Garay RP, El-Gewely MR, Labaune J-P, Richette P. Therapeutic perspectives on uricases for gout. Joint Bone Spine 2012;79:237-42
   PubMed Web of Science ®Google Scholar
• Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59-68
   PubMed Web of Science ®Google Scholar
• 3SBio. 3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million. The Medical News: News-Medical. Net; 2010
   Google Scholar
• da Silva Freitas D, Spencer PJ, Vassao RC, Abrahao-Neto J. Biochemical and biopharmaceutical properties of PEGylated uricase. Int J Pharm 2010;387:215-22
   PubMed Web of Science ®Google Scholar
• Tan QY, Wang N, Yang H, Characterization, stabilization and activity of uricase loaded in lipid vesicles. Int J Pharm 2010;384:165-72
   PubMed Web of Science ®Google Scholar
• Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci (USA) 1989;86:9412-16
   PubMed Web of Science ®Google Scholar
• Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. In: El-Gewely MR, editor. Biotechnology annual review. Elsevier, Amsterdam; 2008. p. 191-202
   Google Scholar
• El-Gewely MR, Fenton C, Kjeldsen E, Xu H. Mutagenesis: site-specific encyclopedia of life sciences. Nature Publishing Group & Wiley, Chichester (UK); 2005. p. 1-12
   Google Scholar
• Garratty G. Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion. Vox Sang 2008;94:87; 27-95
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Meiselman HJ, Fisher TC. Covalent binding of poly(ethylene glycol) (PEG) to the surface of red blood cells inhibits aggregation and reduces low shear blood viscosity. Am J Hematol 1997;56:26-8
   PubMed Web of Science ®Google Scholar
• Sherman MR, Williams LD, Sobczyk MA, Role of the Methoxy Group in Immune Responses to mPEG-Protein Conjugates. Bioconjug Chem 2012;23:485-99
   PubMed Web of Science ®Google Scholar
• Sherman MR, Saifer MGP, David Williams L, Next-generation PEGylation enables reduced immunoreactivity of PEG-protein conjugates. Drug Dev Del 2012;12:36-42
   Google Scholar
• Geething NC, To W, Spink BJ, Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS One 2010;5:e10175
   Google Scholar
• Amunix. Available from: www.amunix.com [Accessed 8 August 12]
   Google Scholar
• Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011;22(6):868-76
   PubMed Web of Science ®Google Scholar
• XL-protein. Available from: xl-protein.com ( Accessed 08 August 12)
   Google Scholar
• Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release 2011; [Epub ahead of print]
   Web of Science ®Google Scholar